Intended Use

RSI-MRI+ is indicated for use as automatic post-acquisition image processing software for analysis of diffusion-weighted and anatomical magnetic resonance imaging data. It is intended for automatic fusion of derived diffusion-weighted MRI data with anatomical T2-weighted MR images and provides automatic prostate segmentation, quantification, and reporting of derived image metrics. Not intended for pediatric populations or to diagnose, treat or prevent diseases.

Technology

RSI-MRI+ is standalone software that accepts DICOM images, performs diffusion-weighted MRI analysis with a Restricted Signal Map for improved conspicuity, fuses diffusion data with anatomical T2-weighted MR images, and uses AI deep learning for automatic prostate segmentation and automated reporting. Outputs are standard DICOM format compatible with commercial PACS systems.

Performance

Software verification and validation testing confirmed that RSI-MRI+ operates as intended, processing DICOM images and producing expected outputs. Performance testing demonstrated increased conspicuity of the Restricted Signal Map, accuracy of automated prostate segmentation compared to manual radiologist segmentations, and diffusion signal normalization across scanners. Testing used retrospective labeled clinical data and met predetermined acceptance criteria, demonstrating safety and effectiveness.

Predicate Devices

No predicate devices specified

Device Timeline

  • 1

    Submission

    5/13/2019

    6 months
  • 2

    FDA Approval

    11/19/2019

Ready to Sharpen Your Edge?

Join hundreds of your peers who rely on RadAI Slice. Get the essential weekly briefing that empowers you to navigate the future of radiology.

We respect your privacy. Unsubscribe at any time.